Isovalerylspiramycin I alleviates liver injury and liver fibrosis by targeting the nucleotide-binding protein 2 (NUBP2)-vascular non-inflammatory molecule-1 (VNN1) pathway
Article in Journal of Pharmaceutical Analysis (July 2024)
The most recent citing publications are shown below. View all 11 publications that cite this research output on Dimensions.
Article in Journal of Pharmaceutical Analysis (July 2024)
Article in Acta Pharmaceutica Sinica B (March 2024)
Article in Chinese Journal of Natural Medicines (March 2024)